Corcym has announced the first-in-human implant of Memo 4D Curve, a semi-rigid open-configuration annuloplasty ring for mitral valve repair. The procedure, a robotic cardiac surgery, was performed by Michael Ibrahim at UVA Health University Medical Center (Charlottesville, USA).
Memo 4D Curve builds upon Corcym’s existing annuloplasty platform, incorporating a nitinol-based semi-rigid annuloplasty design, now with availability in an open configuration. The system is designed to preserve the natural three-dimensional motion of the mitral annulus while providing the support to remodel it, and is available in sizes up to 42 mm.
“Performing the first implant of Memo 4D Curve is an exciting moment for our team,” said Ibrahim. “Having the Memo platform available in an open configuration gives us another option when performing mitral valve repair.”
“With this milestone, the Memo platform takes another step forward, giving surgeons greater choice in mitral valve repair and reaffirming our ongoing commitment to advancing the field alongside the cardiac surgery community,” said Christian Mazzi, CEO of Corcym.
Memo 4D Curve is US Food and Drug Administration (FDA) cleared and commercially available in the USA. Corcym will be launching the device at the European Association of Cardio-Thoracic Surgery (EACTS) annual meeting (7–10 October, Barcelona, Spain).
Corcym also recently announced the first-in-human use of TriMemo, a semi-rigid annuloplasty ring dedicated to tricuspid valve repair.
